Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Community Trust & Investment Co.


Share on StockTwits

Community Trust & Investment Co. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,284 shares of the medical research company’s stock after purchasing an additional 1,965 shares during the quarter. Community Trust & Investment Co.’s holdings in Thermo Fisher Scientific were worth $12,908,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of TMO. Norges Bank purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $2,336,640,000. FMR LLC grew its holdings in Thermo Fisher Scientific by 5.6% during the fourth quarter. FMR LLC now owns 13,022,987 shares of the medical research company’s stock worth $6,065,847,000 after acquiring an additional 686,768 shares during the period. BlackRock Inc. raised its position in Thermo Fisher Scientific by 2.2% in the fourth quarter. BlackRock Inc. now owns 29,504,221 shares of the medical research company’s stock worth $13,742,475,000 after acquiring an additional 624,512 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich boosted its position in shares of Thermo Fisher Scientific by 473.7% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 641,921 shares of the medical research company’s stock worth $298,994,000 after purchasing an additional 530,026 shares in the last quarter. Finally, Veritas Investment Partners UK Ltd. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $156,804,000. 87.17% of the stock is owned by hedge funds and other institutional investors.

Shares of TMO stock traded up $16.34 during mid-day trading on Friday, reaching $494.38. The company’s stock had a trading volume of 2,375,756 shares, compared to its average volume of 1,815,905. The company’s 50 day simple moving average is $455.81 and its 200-day simple moving average is $472.99. The company has a quick ratio of 2.31, a current ratio of 2.93 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a 12-month low of $316.36 and a 12-month high of $532.57. The firm has a market capitalization of $194.30 billion, a PE ratio of 40.52, a price-to-earnings-growth ratio of 1.40 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Sunday, January 31st. The medical research company reported $7.09 EPS for the quarter, beating the consensus estimate of $6.56 by $0.53. Thermo Fisher Scientific had a return on equity of 21.35% and a net margin of 17.12%. The business had revenue of $10.55 billion for the quarter, compared to the consensus estimate of $9.53 billion. During the same period last year, the business posted $3.55 EPS. The company’s revenue was up 54.5% on a year-over-year basis. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 19.03 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 16th. Stockholders of record on Tuesday, March 16th will be given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.21%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. The ex-dividend date is Monday, March 15th. Thermo Fisher Scientific’s payout ratio is presently 8.42%.

Several brokerages have weighed in on TMO. BTIG Research upped their target price on shares of Thermo Fisher Scientific from $540.00 to $590.00 and gave the stock a “buy” rating in a research report on Wednesday, February 3rd. Citigroup raised their price objective on Thermo Fisher Scientific from $500.00 to $530.00 and gave the company a “buy” rating in a research note on Tuesday, February 2nd. Barclays started coverage on Thermo Fisher Scientific in a research report on Monday, March 8th. They set an “overweight” rating and a $525.00 target price on the stock. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $488.00 price target for the company. in a research report on Tuesday, December 22nd. Finally, SVB Leerink increased their price objective on shares of Thermo Fisher Scientific from $525.00 to $560.00 and gave the company an “outperform” rating in a research note on Tuesday, February 2nd. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $524.45.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading: Special Dividends

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.